In an adult with treatment‑resistant major depressive disorder and a history of a suicide attempt, who is currently on fluoxetine 80 mg daily, lithium 600 mg daily, and buspirone 5 mg three times daily, is it appropriate to increase lithium to 900 mg and check a serum lithium level five days after the dose change?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Increasing Lithium to 900mg is Appropriate with Proper Monitoring

Yes, increasing lithium from 600mg to 900mg is appropriate in this clinical scenario, but lithium levels should be checked 5-7 days after the dose increase to ensure therapeutic levels and monitor for toxicity 1.

Rationale for Lithium Augmentation

This patient presents with treatment-resistant depression (TRD) and a history of suicide attempt—two critical factors that make lithium augmentation particularly appropriate:

Evidence for Lithium in Treatment-Resistant Depression

Lithium augmentation of antidepressants is strongly supported by evidence 2. When added to antidepressants like fluoxetine, lithium demonstrates significantly greater efficacy than placebo (p<0.0001) 2. This patient is already on fluoxetine 80mg (maximum dose), making augmentation the logical next step rather than switching agents 3.

Critical Anti-Suicidal Properties

Lithium has unique and substantial anti-suicidal effects that are particularly relevant given this patient's history 4. Meta-analyses demonstrate that lithium maintenance treatment reduces suicide attempt recurrence 8.6-fold in adults with major affective disorders 4. These effects may be due to lithium's central serotonin-enhancing properties and appear to be unique among mood stabilizers 4. The 2025 VA/DoD guidelines note insufficient evidence to make a definitive recommendation on lithium for suicide risk reduction, but acknowledge the supporting evidence 5.

Dosing and Monitoring Protocol

Dose Increase Strategy

  • The increase from 600mg to 900mg represents a 50% dose escalation, which is reasonable for achieving therapeutic lithium levels (typically 0.6-1.2 mEq/L for augmentation)
  • This dose is within standard therapeutic ranges used in clinical trials 2

Timing of Lithium Level Check

Check lithium levels 5-7 days after the dose change 1. This timing allows:

  • Achievement of steady-state concentrations (lithium has a 24-hour half-life, so steady state occurs in approximately 5 days)
  • Early detection of potential toxicity
  • Dose adjustment if levels are subtherapeutic or supratherapeutic

Important Drug Interaction Considerations

Monitor closely for lithium toxicity given the fluoxetine interaction 1. The FDA label specifically warns that there have been reports of both increased and decreased lithium levels when used concomitantly with fluoxetine, and cases of lithium toxicity have occurred 1. This makes the 5-day level check even more critical.

Clinical Monitoring Requirements

Given the suicide risk and medication changes, implement the following:

  • Immediate monitoring: Assess patient status within 1-2 weeks of any dose change for worsening depression, suicidal ideation, agitation, or unusual behavioral changes 3
  • Lithium-specific monitoring: Check for signs of lithium toxicity (tremor, confusion, ataxia, polyuria, polydipsia)
  • Renal function: Ensure baseline and periodic creatinine monitoring, as lithium is renally excreted
  • Thyroid function: Monitor TSH periodically, as lithium can cause hypothyroidism

Common Pitfalls to Avoid

  1. Inadequate plasma lithium levels: Studies show difficulty achieving adequate plasma lithium levels is common 6. Don't assume 900mg will be sufficient—adjust based on serum levels and clinical response

  2. Premature discontinuation: If lithium is discontinued, there is a 7-fold increase in suicide attempt rate and 9-fold increase in suicide rate 4. Any future discontinuation must be gradual and carefully monitored

  3. Overlooking the high-risk period: The risk for suicide attempts is greatest during the first 1-2 months of antidepressant treatment 3. This patient requires close monitoring regardless of the lithium increase

  4. Ignoring the buspirone: At only 5mg TID (15mg total daily), buspirone is at a subtherapeutic dose for anxiety augmentation (typical range 30-60mg/day). Consider whether this medication is providing benefit or could be optimized

Expected Timeline for Response

  • Lithium augmentation response: Typically occurs within 2-4 weeks if effective 6, 2
  • Reassessment point: If no adequate response within 6-8 weeks of the lithium increase, consider additional treatment modifications 3

Safety Considerations

Lithium requires careful third-person supervision due to lethal overdose potential 4. Ensure:

  • Prescriptions are written for the smallest quantity consistent with good patient management
  • Family/caregivers are educated about signs of toxicity
  • Lethal means restriction is addressed (firearms, medications)

The combination of treatment-resistant depression and prior suicide attempt makes this a high-stakes clinical situation where lithium's dual benefits—augmenting antidepressant response and reducing suicide risk—are particularly valuable.

Related Questions

How should I manage an 18‑year‑old lactating female with depression who is taking fluoxetine 30 mg and risperidone 1 mg and feels fluoxetine worsens her paranoid thoughts?
In a 19‑year‑old female with anxiety, depression, ADHD symptoms and possible bipolar or cyclothymic disorder who is currently taking fluoxetine 60 mg and buspirone 10 mg, is sertraline an appropriate option and does she need to taper off fluoxetine before starting sertraline?
In a 53-year-old non‑verbal adult with intellectual disability who has been yelling continuously for 8 hours while taking valproic acid (2.5 mL oral solution), quetiapine (Seroquel) 25 mg at bedtime, fluoxetine 20 mg daily, and diazepam 5 mg twice daily, what medication adjustments or new prescriptions are recommended to control the agitation?
In a 76‑year‑old female on rehabilitation with major depressive disorder, generalized anxiety disorder, and seizure disorder treated with lamotrigine (200 mg twice daily), currently receiving vortioxetine (20 mg daily), buspirone (22.5 mg twice daily), and olanzapine (Zyprexa) (2.5 mg daily) after discontinuation of lorazepam (Ativan), how should her mood and anxiety be managed?
In a 16-year-old female who developed excessive drowsiness after increasing Luvox (fluvoxamine) from 50 mg to 75 mg, how should the sedation be managed?
How should a 45-year-old with newly diagnosed rheumatic heart disease, severe mitral stenosis, moderate mitral regurgitation, moderate aortic regurgitation, and a marked blood‑pressure discrepancy (right arm 120/50 mm Hg, left arm ~20 mm Hg by palpation) be managed?
In a patient taking desvenlafaxine, buspirone, temazepam, divalproex, duloxetine, levothyroxine, and oxbutynin, which of these medications are likely causing hyponatremia and what is the recommended management?
What steps should I take during a patient appointment to assess and safely refill Adderall (amphetamine) for ADHD?
How should silodosin and mirabegron be used together to treat a patient with benign prostatic hyperplasia‑related voiding difficulty and overactive bladder, including appropriate dosing, contraindications, and monitoring?
When should a patient with ADHD be referred to a psychiatrist and what other groups or services can assist?
What is the recommended wound care protocol for treating diabetic foot or leg wounds and burn wounds that have progressed to ulceration?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.